Navigation Links
Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
Date:9/13/2011

FORT WORTH, Texas, Sept. 13, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming UBS Global Life Sciences Conference. The presentation is scheduled for the opening day of the conference, Monday, September 19th, at 3 pm (EDT) at the Grand Hyatt in New York City.

The presentation will include updates on the Company's ongoing commercial operations, its recent acquisition of Regranex® Gel and Phase 2b summary results for its cell therapy pipeline candidate for venous leg ulcers (HP802-247).

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is presently centered around next-generation cell-based therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® Gel. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.

HEALTHPOINT, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.


'/>"/>
SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Healthpoint Biotherapeutics Acquires Regranex® Gel
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... KONG , Dec. 9, 2016 China Cord ... "Company"), China,s leading provider of cord ... cell storage services, today announced the results of its 2016 ... in Hong Kong S.A.R., China . ... ratified the re-appointment of KPMG Huazhen LLP as ...
(Date:12/8/2016)... , Dec. 8, 2016  The Board of ... (PLSG), Western Pennsylvania,s only pure ... leadership. In accordance with the succession plan developed by ... years, effective today, James (Jim) F. Jordan ... Officer, succeeding John W. Manzetti , who is ...
(Date:12/8/2016)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today announced financial results for the fiscal first ... on our commitment to address an unmet medical ... pleased with the early clinical response data presented ... focused on advancing our lead program – ImmunoPulse® ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
Breaking Biology Technology:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):